National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 38906-38907 [2020-13884]

Download as PDF 38906 Federal Register / Vol. 85, No. 125 / Monday, June 29, 2020 / Notices Composition The HITAC is comprised of at least 25 members, of which: • No fewer than 2 members are advocates for patients or consumers of health information technology; • 3 members are appointed by the HHS Secretary Æ 1 of whom shall be appointed to represent the Department of Health and Human Services and Æ 1 of whom shall be a public health official; • 2 members are appointed by the majority leader of the Senate; • 2 members are appointed by the minority leader of the Senate; • 2 members are appointed by the Speaker of the House of Representatives; • 2 members are appointed by the minority leader of the House of Representatives; and • Other members are appointed by the Comptroller General of the United States. Members will serve for one-, two-, or three-year terms. All members may be reappointed for a subsequent three-year term. Each member is limited to two three-year terms, not to exceed six years of service. After establishment, members shall be appointed for a three-year term. Members serve without pay, but will be provided per-diem and travel costs for committee services. Recommendations The HITAC recommendations to the National Coordinator are publicly available at https://www.healthit.gov/ topic/federal-advisory-committees/ recommendations-national-coordinatorhealth-it. jbell on DSKJLSW7X2PROD with NOTICES Public Meetings The revised schedule of meetings to be held in 2020 is as follows: • January 15, 2020 from approximately 9:30 a.m. to 2:30 p.m./ Eastern Time at the Washington Plaza Hotel, 10 Thomas Circle NW, Washington, DC 20005 • February 19, 2020 from approximately 9:30 a.m. to 2:30 p.m./ Eastern Time (virtual meeting) • March 18, 2020 from approximately 9:30 a.m. to 2:30 p.m./Eastern Time (virtual meeting) • March 26, 2020 from approximately 10:30 a.m. to 1:30 p.m./Eastern Time (virtual meeting) • April 15, 2020 from approximately 9:30 a.m. to 2:30 p.m./Eastern Time (virtual meeting) • May 20, 2020 from approximately 9:30 a .m. to 2:30 p.m./Eastern Time (virtual meeting) VerDate Sep<11>2014 20:25 Jun 26, 2020 Jkt 250001 •(June 17, 2020 from approximately 9:30 a.m. to 2:30 p.m./Eastern Time (virtual meeting) • September 9, 2020 from approximately 9:30 a.m. to 2:30 p.m./ Eastern Time (virtual meeting) • October 21, 2020 from approximately 9:30 a.m. to 2:30 p.m./ Eastern Time (virtual meeting) • November 10, 2020 from approximately 9:30 a.m. to 2:30 p.m./ Eastern Time (virtual meeting) All meetings are open to the public. Additional meetings may be scheduled as needed. For web conference instructions and the most up-to-date information, please visit the HITAC calendar on the ONC website,https:// www.healthit.gov/topic/federaladvisory-committees/hitac-calendar. Contact Person for Meetings: Lauren Richie, lauren.richie@hhs.gov . A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Please email Lauren Richie for the most current information about meetings. Agenda: As outlined in the 21st Century Cures Act, the HITAC will develop and submit recommendations to the National Coordinator on the topics of interoperability, privacy and security, and patient access. In addition, the committee will also address any administrative matters and hear periodic reports from ONC. ONC intends to make background material available to the public no later than 24 hours prior to the meeting start time. If ONC is unable to post the background material on its website prior to the meeting, the material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on ONC’s website after the meeting, at https://www.healthit.gov/hitac. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person prior to the meeting date. An oral public comment period will be scheduled at each meeting. Time allotted for each presentation will be limited to three minutes. If the number of speakers requesting to comment is greater than can be reasonably accommodated during the scheduled public comment period, ONC will take written comments after the meeting. Persons attending ONC’s HITAC meetings are advised that the agency is not responsible for providing wireless access or access to electrical outlets. PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 ONC welcomes the attendance of the public at its HITAC meetings. Seating is limited at the location, and ONC will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Lauren Richie at least seven (7) days in advance of the meeting. Notice of these meetings are given under the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App. 2). Dated: June 23, 2020. Cassandra Hadley, Office of Policy, Office of the National Coordinator for Health Information Technology. [FR Doc. 2020–13978 Filed 6–26–20; 8:45 am] BILLING CODE 4150–45–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NHP MHC and KIR Allele Discovery and Typing Technology Development. Date: July 21, 2020. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41 Rockville, MD 20892 (Virtual Meeting). Contact Person: Tara Capece, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41 Rockville, MD 20852 301–761–7854 capecet2@ niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, E:\FR\FM\29JNN1.SGM 29JNN1 Federal Register / Vol. 85, No. 125 / Monday, June 29, 2020 / Notices and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: June 23, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. National Institutes of Health [FR Doc. 2020–13884 Filed 6–26–20; 8:45 am] Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c) (4) and 552b(c) (6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. jbell on DSKJLSW7X2PROD with NOTICES Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Function, Integration, and Rehabilitation Sciences Subcommittee. Date: October 19, 2020. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: NIH/NICHD, 6710 B Rockledge Drive, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Helen Huang, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20817, 301–435–8380, helen.huang@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: June 22, 2020. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–13835 Filed 6–26–20; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 20:25 Jun 26, 2020 Jkt 250001 National Cancer Institute; Notice of Closed Meeting Name of Committee: National Cancer Institute Special Emphasis Panel; JUN2020 Cycle 35 NExT SEP Committee Meeting. Date: August 5, 2020. Time: 9:00 a.m. to 3:00 p.m. Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Room 3A44, Bethesda, MD 20892 (Teleconference Call). Contact Persons: Barbara Mroczkowski, Ph.D., Executive Secretary, Discovery Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20817, (301) 496–4291, mroczkoskib@mail.nih.gov. Toby Hecht, Ph.D., Executive Secretary, Development Experimental Therapeutics Program, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 3W110, Rockville, MD 20850, (240) 276–5683, toby.hecht2@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 38907 Dated: June 23, 2020. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–13834 Filed 6–26–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2020–0278] Port Access Route Study: Northern New York Bight Coast Guard, DHS. Notice of study and public meetings; request for comments. AGENCY: ACTION: The Coast Guard is conducting a Port Access Route Study (PARS) to evaluate the adequacy of existing vessel routing measures and determine whether additional vessel routing measures are necessary for port approaches to New York and New Jersey and international and domestic transit areas in the First District area of responsibility. The Northern New York Bight PARS (NNYBPARS) will consider whether existing or additional routing measures are necessary to improve navigation safety due to factors such as planned or potential offshore development, current port capabilities and planned improvements, increased vessel traffic, existing and potential anchorage areas, changing vessel traffic patterns, effects of weather, or navigational difficulty. Vessel routing measures, which include traffic separation schemes, two-way routes, recommended tracks, deep-water routes, precautionary areas, and areas to be avoided, are implemented to reduce the risk of marine casualties. The recommendations of the study may subsequently be implemented through rulemakings or in accordance with international agreements. DATES: Comments and related material must be received on or before August 28, 2020. Although the Coast Guard prefers and highly encourages all comments and related material be submitted directly to the electronic docket, two virtual public meetings will be held via webinar and teleconference to provide an opportunity for oral comments about the NNYBPARS on Thursday, July 30, 2020, beginning at 9 a.m. EST, and on Tuesday, August 11, 2020, beginning at 6 p.m. EST. All comments and related material submitted must be received by the Coast Guard on or before August 28, 2020. SUMMARY: E:\FR\FM\29JNN1.SGM 29JNN1

Agencies

[Federal Register Volume 85, Number 125 (Monday, June 29, 2020)]
[Notices]
[Pages 38906-38907]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-13884]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NHP MHC and KIR Allele Discovery 
and Typing Technology Development.
    Date: July 21, 2020.
    Time: 11:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G41 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Tara Capece, Ph.D., Scientific Review Officer, 
Scientific Review Program, Division of Extramural Activities, 
National Institute of Allergy and Infectious Diseases, National 
Institutes of Health, 5601 Fishers Lane, Room 3G41 Rockville, MD 
20852 301-761-7854 [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology,

[[Page 38907]]

and Transplantation Research; 93.856, Microbiology and Infectious 
Diseases Research, National Institutes of Health, HHS)

    Dated: June 23, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-13884 Filed 6-26-20; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.